viewSareum Holdings PLC

Sareum Holdings jumps as it says new data on cancer drug to be released at top conference

The update is being presented in the form of two abstracts at the American Society of Clinical Oncology in Chicago

ovarian cancer graphic
Being trialled are two different approaches to treating ovarian cancer

Sareum Holdings PLC (LON:SAR) shares jumped on Tuesday as the firm said data from a potential cancer drug it developed will be showcased at the world’s leading oncology conference.

Updated results from a Phase I/IIa studies carried out on SRA737 by licensing partner Sierra Oncology will be delivered in the form of two abstracts at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1.

The Sareum-discovered drug candidate is what’s known as a checkpoint kinase 1 (CHK1) inhibitor.

CHK1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally by chemotherapy or radiotherapy.

The new treatment is being trialled in women with ovarian cancer, both as a single therapy and in harness with chemotherapy called gemcitabine.

The ASCO abstracts cover new data on the two approaches to treating the killer disease.

In afternoon trading, Sareum shares were 7.1% higher at 0.75p.

 -- Adds share price --

Quick facts: Sareum Holdings PLC

Price: 0.539 GBX

Market: AIM
Market Cap: £17.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...



Sareum Holdings says Phase I clinical trials for CHK1 could potentially...

Tim Mitchell, chief executive officer at cancer drug discovery company Sareum Holdings (LON:SAR), talks to Proactive Investors about the progress achieved by all of its programmes in the half year ended December 31, 2015. He says Phase I clinical trials for CHK1, its most advanced...

on 02/24/2016

2 min read